Clinical Trials

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT04650581 2026-04-13

FINER

250 enrolled 13 charts

Breast Neoplasms

NCT04251533 2026-04-03

EPIK-B3

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT02445391 2026-04-01

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

415 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

466 enrolled 17 charts

HER2-positive Breast Cancer

NCT00099437 2026-03-18

CONFIRM

736 enrolled 14 charts

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

624 enrolled 17 charts

Breast Neoplasms

NCT01349322 2026-03-05

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

2,354 enrolled 29 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 3 FDA

Breast Neoplasms

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

608 enrolled 17 charts

Breast Neoplasms

NCT03414970 2026-02-24

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

898 enrolled 13 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT02032823 2026-02-17

OlympiA

1,836 enrolled 20 charts 2 FDA

Breast Neoplasms

NCT02000622 2026-02-13

OlympiAD

302 enrolled 26 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02947685 2026-02-12

PATINA

518 enrolled 15 charts

Breast Neoplasms

NCT04739761 2026-02-11

DESTINY-B12

506 enrolled 27 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02513394 2026-02-10

PALLAS

5,796 enrolled 14 charts

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT00066690 2026-02-06

SOFT

3,066 enrolled 15 charts

Breast Neoplasms

NCT00066703 2026-02-06

TEXT

2,672 enrolled 14 charts

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02246621 2026-02-03

MONARCH 3

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT04305496 2026-01-29

CAPItello-291

818 enrolled 19 charts 2 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

190 enrolled 12 charts

Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT02115282 2025-12-18

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 2 FDA

Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT02297438 2025-10-27

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

340 enrolled 29 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

524 enrolled 11 charts 2 FDA

Breast Neoplasms

NCT00210236 2025-10-20

AXIL95

625 enrolled 8 charts

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03367572 2025-09-25

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

1,363 enrolled 20 charts

Breast Neoplasms

NCT00210210 2025-09-19

KETAMINE

230 enrolled 6 charts

Agnosia, Breast Neoplasms, Pain, Postoperative

NCT05128773 2025-09-16

AMEERA-6

3 enrolled 3 charts

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 2 FDA

Breast Neoplasms

NCT04478266 2025-09-11

AMEERA-5

1,068 enrolled 21 charts

Breast Neoplasms

NCT04815083 2025-09-03

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

57 enrolled 8 charts

Breast Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

315 enrolled 11 charts

Breast Neoplasms

NCT04740918 2025-08-08

KATE3

96 enrolled 16 charts

Breast Neoplasms

NCT00070564 2025-07-31

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

3,294 enrolled 22 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

1,486 enrolled 37 charts 2 FDA

Breast Neoplasms

NCT04915755 2025-07-16

ZEST

40 enrolled 13 charts